Overall Efficacy
- Effect Size: Cobenfy’s overall efficacy on the Positive and Negative Syndrome Scale (PANSS) stands at an effect size of 0.6, which is higher than many established antipsychotics (typically 0.3-0.5). However, clozapine still leads as the gold standard, with effect sizes ranging from 0.76 to 1.0.
- NNT (Number Needed to Treat): The estimated NNT for Cobenfy is around 4, placing it in the mid-range among antipsychotics, where NNTs often range from 3 to 10.
Negative Symptom Impact
- Cobenfy shows a notable efficacy in reducing negative symptoms. It achieves an impressive effect size of 1.18for this symptom domain, which is uncommon among antipsychotics. This improvement in negative symptoms appears to be independent of reductions in positive symptoms, a distinct advantage over traditional agents.
- The NNT for negative symptoms specifically is around 2, highlighting Cobenfy’s potential as a robust option for patients struggling with these challenging symptoms.
Onset of Action
- Rapid Onset: Cobenfy begins to show statistically significant improvements by week 3.
- Peak Effect: Maximal symptom improvement is typically observed by week 5.
Conclusion
Cobenfy offers strong efficacy in schizophrenia, with unique advantages for negative symptoms. While clozapine remains unmatched in treatment-resistant cases, Cobenfy provides a promising option, especially for patients with significant negative symptoms.